GlassScriptPhysician profile
Sidney Neimark
NPI 1740278522
$4,187.78
in general payments reported to CMS, 2019-2025
29 companies · $1,051 in 2025
The $1,051 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $150 · 2021: $149 · 2022: $425 · 2023: $790 · 2024: $1,173 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,013.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,019.27 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $713.39 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $363.29 | 2019-2025 | Tremfya, Stelara, Simponi |
| Merck Sharp & Dohme LLC | $228.44 | 2019-2024 | Dificid |
| Pfizer INC. | $224.52 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.81 | 2019-2025 | Xifaxan |
| Ardelyx, INC. | $174.17 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $152.86 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $122.92 | 2021-2024 | |
| Ferring Pharmaceuticals INC. | $105.27 | 2019-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $103.78 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $99.47 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $86.80 | 2020-2022 | |
| Celgene Corporation | $79.87 | 2022-2023 | Zeposia |
| Genzyme Corporation | $64.14 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $53.49 | 2022-2024 | Dupixent |
| Aimmune Therapeutics, INC. | $52.98 | 2024 | |
| Intercept Pharmaceuticals, INC. | $51.01 | 2019-2024 | Ocaliva |
| Ucb, INC. | $42.12 | 2019 | |
| Fresenius Kabi USA, LLC | $39.35 | 2023 | Idacio |
| Medtronic, INC. | $37.97 | 2023-2025 | Interstim |
| Madrigal Pharmaceuticals | $30.19 | 2024 | Resmetirom |
| Csl Behring | $23.90 | 2022 | |
| Amgen INC. | $23.65 | 2022 | |
| Boston Scientific Corporation | $22.00 | 2025 | General - Biopsy |
| Vivus LLC | $20.27 | 2023 | Qsymia |
| Biocon Biologics INC | $19.08 | 2025 | Yesintek |
| Allergan, INC. | $17.91 | 2019 | |
| Braintree Laboratories, INC. | $15.86 | 2023 | Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Neimark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.